Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types

British Journal of Cancer

Volumn 110, Issue 11, 2014, Pages 2804-2811

  Kavanagh, K ^a   Pollock, K G J ^b   Potts, A ^b   Love, J ^b   Cuschieri, K ^c   Cubie, H ^c   Robertson, C ^a,b,d   Donaghy, M ^b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

^c Scottish Human Papillomavirus Reference Laboratory   (United Kingdom)

^d INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

human papillomavirus; impact; prevalence; vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; CROSS-SECTIONAL STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNIZATION; INFECTION RISK; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; SCREENING; TREATMENT OUTCOME; WART VIRUS; WART VIRUS 51; WART VIRUS 56;

CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINE POTENCY; YOUNG ADULT;

EID: 84901636857     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.198     Document Type: Article

References (30)

1. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. WHO International Agency for Research on Cancer Monograph Working Group (2009) A review of human carcinogens-Part B: biological agents. Lancet Oncol 10: 321-322.
2. Brotherton JML, Fridman M, May CL, Chappell G, Saville AM, Gertig DM (2011) Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377: 2085-2092.
3. Baker D, Middleton E (2003) Cervical screening and health inequality in England in the 1990s. J Epidemiol Community Health 57: 417-423.
4. CDC (2011) National and state vaccination coverage among adolescents aged 13 through 17-United States, 2010. MMWR 60: 1117-1123.
5. Cuschieri K, Brewster DH,Williams ARW, Brewster DH, Williams AR, Millan D, Murray G, Nicoll S, Imrie J, Hardie A, Graham C, Cubie HA (2010) Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccines. Br J Cancer 102: 930-932.
6. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andújar M, Castellsagué X, Sánchez GI, Nowakowski AM, Bornstein J, Muñoz N, Bosch FX. Retrospective International Survey and HPV Time Trends Study Group (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11: 1048-1056.
7. Junor E, Kerr G, Oniscu A, Campbell S, Kouzeli I, Gourley C, Cuschieri K (2012) Benefit of chemotherapy as part of treatment for HPV DNApositive but p16-negative squamous cell carcinoma of the oropharynx. Br J Cancer 106: 358-365.
8. Kavanagh K, Sinka K, Cuschieri K, Love J, Potts A, Pollock KG, Cubie H, Donaghy M, Robertson C (2013) Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact. BMC Infect Dis 13: 519.
9. Kim J, Lowy D, Smith-McCune KK, Melief CJM (2012) The Value of HPV Vaccination. Nat Med 18: 28-29.
10. Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jiménez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R. CVT Vaccine Group (2011a) Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol 12: 862-870.
11. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S. CVT Vaccine Group. (2011b) Proof-of-principle evaluation of the efficacy of fewer than three doses of 831 a bivalent HPV16/18 vaccine. J Natl Cancer Inst 103: 1444-1451832.
12. Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, Brotherton JM (2012) Human papillomavirus vaccine introduction-the first five years. Vaccine 30(Suppl 5): F139-F148.
13. National Records of Scotland (2012) 2011 Census: First Results on Population Estimates for Scotland-Release 1A. http://www.scotlandscensus.gov.uk/ documents/censusresults/release1a/rel1asb.pdf (accessed 04/07/13).
14. National Services Scotland ISD (2013) Scottish Cervical Screening Programme Statistics 2012-13 https://isdscotland.scot.nhs.uk/Health-Topics/ Cancer/Publications/2013-08-27/2013-08-27-Cervical-Screening-report.pdf? 65131777525[accessed 05/02/14].
15. O'Leary MC, Sinka K, Robertson C, Cuschieri K, Lyman R, Lacey M, Potts A, Cubie HA, Donaghy M (2011) HPV type-specific prevalence using a urine assay in unvaccinated male and female 11-to 18-year olds in Scotland. Brit J Cancer 104: 1221-1226.
16. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
17. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030-3044.
18. Pollock K, Potts A, Love J, Cuschieri K, Cubie H, Kavanagh K, Robertson C, Cruickshank M, Donaghy M (2013) Early effect of the HPV bivalent vaccine on high-risk HPV prevalence and high-grade cervical abnormalities in Scotland. Proc EuroGINhttp://www.eurogin.com/2013/images/pdf/EUROGIN-2013-Abstracts-Part-2. pdf[accessed 05/01/14].
19. Romanowski B (2011) Long-term protection against cervical infection with human papillomavirus. Review of currently available vaccines. Hum Vaccin 7(2): 161-169.
20. Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B, Descamps D (2012) Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 8(3): 390-397.
21. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T (2006) Bead based multiplex genotyping of human papillomaviruses. J Clin Microbiol 44: 504-512.
22. Scottish Government (2005) Scottish Neighbourhood Statistics Guide. http://www.scotland.gov.uk/Publications/2005/02/20697/52626. Accessed online 28 October 2013.
23. Scottish Government (2012) Scottish Index of Multiple Deprivation. http://www.scotland.gov.uk/Topics/Statistics/SIMD. Accessed online 28 October 2013.
24. Sinka K, Kavanagh K, Gordon R, Love J, Potts A, Donaghy M, Robertson C (2014) Achieving high and equitable coverage of adolescent HPV vaccine in Scotland. J Epidemiol Community Health 68: 57-63.
25. Sinka K, Lacey M, Robertson C, Kavanagh K, Cuschieri K, Nicholson D, Donaghy M (2011) Acceptability and response to a postal survey using self-taken samples for HPV vaccine impact monitoring. Sex Transm Infect 87(7): 548-552.
26. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 21: 621-632.
27. Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, Chow SN, Paavonen J, Del Rosario-Raymundo MR, Teixeira JC, De Carvalho NS, Castro-Sanchez M, Castellsagué X, Poppe WA, De Sutter P, Huh W, Chatterjee A, Tjalma WA, Ackerman RT, Martens M, Papp KA, Bajo-Arenas J, Harper DM, Torné A, David MP, Struyf F, Lehtinen M, Dubin G (2013) Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk hpv types (PATRICIA randomized trial): an unexpected observation. J Infect Dis 208(9): 1391-1396.
28. Tota JE, Ramanakumar AV, Jiang M, Dillner J, Walter SD, Kaufman JS, Coutlée F, Villa LL, Franco EL. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol (2013) 178(4): 625-634.
29. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM (2012) Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 206: 1645-1651.
30. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M. HPV PATRICIA Study Group (2012) Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13: 100-110.